In one of the first efforts, CAR‐T‐cell therapy targeting CD33 was performed in a patient with relapsed or refractory AML and reported that the tumor burden of this patient was significantly decreased in the bone marrow after anti‐CD33 CAR‐T‐cell therapy.69 This evidence concerns the gene CD33 and acute myeloid leukemia.